Accrol Group Holdings PLC Turnaround complete

Accrol Group Holdings plc
[shareaholic app="share_buttons" id_name="post_below_content"]

Accrol Group Holdings (LON:ACRL) results came in as expected at the headline level, with adjusted EBITDA (post IFRS 16) of £3.2m (adj. EBITDA of £1.9m pre-IFRS 16), which compared to a £1.1m loss last year at the adjusted EBITDA level. Encouragingly net debt is now reducing at an accelerated rate ahead of our expectations, with adjusted EBITDA on track.  However, interest costs are £0.6m higher than our previous expectations for FY, which triggers a 7.9% EPS downgrade in 2020 and 6.1% and 3.1% in 2021 and 2022 respectively. Our intrinsic value analysis implies a valuation range of £89.8m – £139.1m (vs. a current market cap of £60.5m).

  • Interim results: In the six months ended 31 October 2019, revenue was up 13% to £65.1m (H1 19: £57.6m), on a like for like basis (which excludes discontinued AFH activities) revenue was up 20% to £64.5m (H1 19: £53.9m). The gross margin rose by 770bp to 19.7% (H1 19: 12.0%), as operational improvements to efficiency began to flow through.  Operational costs also reduced by a further 11% during the period, contributing to the adjusted EBITDA improvement of £4.3m to £3.2m from a loss of £1.1m in H1 19.  Net debt at 31 October 2019 was reduced to £24.8m, compared with £27.1m at 30 April 2019 with no seasonal weighting. 
  • Progress delivered: Management have successfully turned the business around through reorganisation, cost rationalisation, renegotiations with customers and refinancing. Management believe that they have achieved their primary goal in building a robust, agile and market-leading business, capable of delivering growth and reasonable levels of return to shareholders in the toughest of economic conditions.
  • Forecasts: We leave underlying revenue and EBITDA forecasts unchanged following this update and will wait until the full year results to incorporate the impact of IFRS 16. Our EPS forecasts do fall by 3.1% – 7.9% through the forecast period due to higher interest costs than we anticipated during the period. We also adjust working capital assumptions, reflecting the return of creditor support and now expect net debt to be lower at £19.9m at the end of 2020E (vs £24.8m previously) going to £15.5m in 2021E (vs. £20.0m previously). This is a 22.3% – 59.1% reduction in net debt, and a major positive to the investment thesis in our view.
  • Investment view:  While challenges remain, we see potential for the Group to return to its pre-IPO foundation to build a more efficient and stronger business from here.  Our intrinsic value analysis, based on a revenue base of £150m – £170m at a 10% EBITDA margin, implies a valuation range of £90.6m – £140.2m (vs. a current market cap of £60.5m) implying upside of between 48.4% – 129.9%.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
Accrol Group Holdings plc (LON:ACRL) has announced the publication of a shareholder circular detailing terms of the Scheme. Learn more here.
Discover the latest results and overview of Accrol Group Holdings, the UK's top independent tissue converter, led by CEO Gareth Jenkins and CFO Chris Welsh.
In this interview, Gervais Williams, co-fund manager of Miton UK MicroCap Trust, discusses navigating the economic landscape and standout companies in 2024. Find out more here. #investment #microcap
Accrol Group Holdings plc has reported strong H1 FY24 results, with impressive growth in adjusted EBITDA and adjusted PBT. The company remains on track to meet expectations and has seen gains in market share. Furthermore, the private label segment of the UK tissue market continues to increase, and the sales of biodegradable wet wipes have been exceptionally strong. Accrol's outlook remains positive with expected further volume growth.
Accrol Group Holdings plc has reported strong performance in H1 FY24, with branded volumes rising by 45% and margins returning to pre-pandemic levels. The group is on track to deliver FY24 results in line with expectations and expects to outperform previous expectations for FY25.

Search

Search